TI Medical Unveils its Premium Suture Product Range at MedTech Expo 2025, Bharat Mandapam

TI Medical Unveils its Premium Suture Product Range at MedTech Expo 2025, Bharat Mandapam

TI Medical, one of India’s fastest-growing innovators in the medical technology sector, proudly launched its Premium Suture product range at the MedTech Expo 2025 September 2025 at the iconic Bharat Mandapam in New Delhi. The unveiling was done by Mr. Aseem Sahu, Deputy Drugs Controller, Medical Device Division, alongside Mr. Prashant Krishnan, CEO of TI Medical, and the company’s leadership team.


The unveiling at MedTech Expo 2025 comes at a time when the Indian medical technology sector is experiencing rapid growth and recognition on the world stage. By introducing its Premium Suture Range in such a prestigious platform, TI Medical has reinforced its leadership role and vision of becoming a trusted partner in surgical innovation, not only within India but across global markets.


Speaking at the launch, Mr. Prashant Krishnan, CEO, TI Medical, said “The unveiling of our Premium Suture Range is more than just the introduction of a new product—it is a reaffirmation of our commitment to delivering world-class solutions ‘Made in India, Made for the World.’ At TI Medical, we believe that innovation, quality, and accessibility must go hand in hand to create real impact in healthcare. This premium suture line is designed to meet global standards while being cost-effective and reliable, empowering surgeons across India and worldwide.”


TI Medical is also proud to be a part of the Yamuna Expressway Industrial Development Authority (YEIDA)’s Medical Device Park at Sector 28 — a visionary initiative by the Government of Uttar Pradesh to develop a world-class hub for medical technology. Recognizing the immense growth potential of India’s healthcare sector, TI Medical has been allotted 11 acres of land within the park to support its expansion and innovation efforts.

Close Menu

💡 Enjoying the content?

For getting latest content, Please Follow us.

Follow Us